HK1219731A1 - 喹硫平的氨基酸綴合物、其製備和使用方法 - Google Patents

喹硫平的氨基酸綴合物、其製備和使用方法

Info

Publication number
HK1219731A1
HK1219731A1 HK16107736.6A HK16107736A HK1219731A1 HK 1219731 A1 HK1219731 A1 HK 1219731A1 HK 16107736 A HK16107736 A HK 16107736A HK 1219731 A1 HK1219731 A1 HK 1219731A1
Authority
HK
Hong Kong
Prior art keywords
quetiapine
making
amino acid
same
acid conjugates
Prior art date
Application number
HK16107736.6A
Other languages
English (en)
Inventor
Travis Mickle
Sven Guenther
Sanjib Bera
Original Assignee
Kempharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kempharm Inc filed Critical Kempharm Inc
Publication of HK1219731A1 publication Critical patent/HK1219731A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/16—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D267/18—[b, e]-condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings
    • C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D281/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D281/16—[b, f]-condensed

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HK16107736.6A 2009-12-31 2016-07-04 喹硫平的氨基酸綴合物、其製備和使用方法 HK1219731A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29157609P 2009-12-31 2009-12-31

Publications (1)

Publication Number Publication Date
HK1219731A1 true HK1219731A1 (zh) 2017-04-13

Family

ID=44226775

Family Applications (2)

Application Number Title Priority Date Filing Date
HK15110951.9A HK1210046A1 (zh) 2009-12-31 2015-11-06 喹硫平的氨基酸綴合物、其製備和使用方法
HK16107736.6A HK1219731A1 (zh) 2009-12-31 2016-07-04 喹硫平的氨基酸綴合物、其製備和使用方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK15110951.9A HK1210046A1 (zh) 2009-12-31 2015-11-06 喹硫平的氨基酸綴合物、其製備和使用方法

Country Status (10)

Country Link
US (6) US20110183963A1 (zh)
EP (2) EP2987789A1 (zh)
JP (2) JP5544024B2 (zh)
CN (3) CN102781236B (zh)
AU (1) AU2010336981B2 (zh)
CA (4) CA2785846C (zh)
ES (1) ES2548031T3 (zh)
HK (2) HK1210046A1 (zh)
IL (1) IL220664A (zh)
WO (1) WO2011082076A1 (zh)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102781236B (zh) 2009-12-31 2015-01-07 凯姆制药公司 喹硫平的氨基酸缀合物、其制备和使用方法
DK2544536T3 (en) 2010-03-11 2019-02-04 Kempharm Inc FAT ACID CONJUGATES OF QUETIAPIN, METHOD OF PREPARING IT AND USING IT
PT2888234T (pt) 2012-08-21 2018-02-22 Janssen Pharmaceutica Nv Haptenos de aripiprazol e seu uso em imunoensaios
CN104736567B (zh) 2012-08-21 2019-09-03 詹森药业有限公司 阿立哌唑半抗原的抗体及其用途
EP3556759B1 (en) 2012-08-21 2023-11-29 Janssen Pharmaceutica NV Haptens of paliperidone
JP6131415B2 (ja) 2012-08-21 2017-05-24 ヤンセン ファーマシューティカ エヌ．ベー． イムノアッセイに使用するためのクエチアピンのハプテン
CN104755928B (zh) 2012-08-21 2017-05-10 詹森药业有限公司 奥氮平的抗体及其用途
JP6374387B2 (ja) 2012-08-21 2018-08-15 ヤンセン ファーマシューティカ エヌ．ベー． リスペリドンハプテンへの抗体及びその使用
WO2014031665A1 (en) * 2012-08-21 2014-02-27 Ortho-Clinical Diagnostics, Inc Antibodies to quetiapine haptens and use thereof
PT2888269T (pt) 2012-08-21 2019-01-17 Janssen Pharmaceutica Nv Haptenos de olanzapina
ES2762105T3 (es) 2012-08-21 2020-05-22 Janssen Pharmaceutica Nv Anticuerpos para aripiprazol y uso de los mismos
CA2882615C (en) 2012-08-21 2019-07-09 Ortho-Clinical Diagnostics, Inc. Antibodies to quetiapine and use thereof
JP2015529199A (ja) 2012-08-21 2015-10-05 オルソ−クリニカル ダイアグノスティクス，インコーポレイティド パリペリドンハプテンに対する抗体及びその使用
CN104755479B (zh) 2012-08-21 2016-11-09 詹森药业有限公司 利培酮和帕潘立酮的半抗原
US20140057303A1 (en) 2012-08-21 2014-02-27 Janssen Pharmaceutica Nv Antibodies to Olanzapine Haptens and Use Thereof
TR201816416T4 (tr) 2012-08-21 2018-11-21 Janssen Pharmaceutica Nv Risperidona yönelik antikorlar ve bunların kullanımı.
CA2882490A1 (en) 2012-08-21 2014-02-27 Ortho-Clinical Diagnostics, Inc. Antibodies to paliperidone and use thereof
WO2015081891A1 (en) * 2013-12-06 2015-06-11 Baikang (Suzhou) Co., Ltd Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs
US20170056352A1 (en) 2015-08-25 2017-03-02 Rgenix, Inc. PHARMACEUTICALLY ACCEPTABLE SALTS OF beta-GUANIDINOPROPIONIC ACID WITH IMPROVED PROPERTIES AND USES THEREOF
WO2017106508A1 (en) 2015-12-17 2017-06-22 Janssen Pharmaceutica Nv Antibodies to quetiapine and use thereof
CA3008809A1 (en) 2015-12-17 2017-06-22 Janssen Pharmaceutica Nv Antibodies to risperidone and use thereof
WO2018160178A1 (en) 2017-03-01 2018-09-07 Rgenix, Inc. Pharmaceutically acceptable salts of b-guanidinopropionic acid with improved properties and uses thereof
CN112118747A (zh) * 2017-12-08 2020-12-22 驰若莫塞尔公司 作为甜味剂的色氨酸衍生物
CA3161341A1 (en) 2019-12-11 2021-06-17 Masoud Fakhr Tavazoie Methods of treating cancer
CN111808046B (zh) * 2020-06-30 2022-11-11 杭州同舟生物技术有限公司 一种喹硫平人工半抗原、人工抗原及其制备方法和应用
CN115028986B (zh) * 2022-06-27 2023-06-23 重庆泰山电缆有限公司 电缆护套材料及制备方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4064138A (en) 1975-11-12 1977-12-20 General Mills, Inc. Amino acid derivatives
GB8607684D0 (en) 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
DE69125750D1 (de) * 1990-05-21 1997-05-28 Abbott Lab Fettsäure-Oberflächenaktives-Lungenprotein Konjate
ES2120477T3 (es) * 1992-01-21 1998-11-01 Macrochem Corp Administracion iontoforetica de medicamentos perfeccionada.
GB9403857D0 (en) 1994-03-01 1994-04-20 Scotia Holdings Plc Fatty acid derivatives
US6623752B1 (en) 1996-07-02 2003-09-23 Hexal Ag Patch for transdermal application for pergolid
US6197764B1 (en) * 1997-11-26 2001-03-06 Protarga, Inc. Clozapine compositions and uses thereof
US5955459A (en) 1997-11-26 1999-09-21 Neuromedica, Inc. Fatty acid-antipsychotic compositions and uses thereof
US7060708B2 (en) * 1999-03-10 2006-06-13 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
GB9922271D0 (en) * 1999-09-21 1999-11-17 Zeneca Ltd Formulation
US20070225379A1 (en) 2001-08-03 2007-09-27 Carrara Dario Norberto R Transdermal delivery of systemically active central nervous system drugs
US7375083B2 (en) 2003-09-30 2008-05-20 Shire Llc Pharmaceutical compositions for prevention of overdose or abuse
AU2002323530B2 (en) * 2001-08-31 2007-09-06 The Rockefeller University Method for classification of anti-psychotic drugs
KR20100097224A (ko) 2001-09-27 2010-09-02 라모트 앳 텔 아비브 유니버시티 리미티드 접합된 항-정신병 약물 및 그의 용도
US7544681B2 (en) 2001-09-27 2009-06-09 Ramot At Tel Aviv University Ltd. Conjugated psychotropic drugs and uses thereof
AU2003217676B2 (en) * 2002-02-22 2009-06-11 Takeda Pharmaceutical Company Limited Active agent delivery systems and methods for protecting and administering active agents
US7700561B2 (en) * 2002-02-22 2010-04-20 Shire Llc Abuse-resistant amphetamine prodrugs
US7393920B2 (en) 2003-06-23 2008-07-01 Cem Corporation Microwave-assisted peptide synthesis
MXPA05013869A (es) * 2003-07-02 2006-02-28 Astrazeneca Ab Metabolito de quetiapina.
WO2005002587A1 (en) * 2003-07-02 2005-01-13 Astrazeneca Ab Quetiapine metabolite with antipsychotic activity
CN1925865B (zh) * 2003-09-30 2011-09-14 希拉有限责任公司 防止用药过量或滥用的药物组合物
WO2005041935A1 (en) * 2003-10-21 2005-05-12 Alpharma, Inc. Pharmaceutical formulations containing quetiapine
US20050171088A1 (en) 2004-01-30 2005-08-04 Astrazeneca Ab Treatment of psychoses with dibenzothiazepine antipsychotic
EP1846355B1 (en) 2005-01-27 2009-12-16 Ocean Nutrition Canada Limited Fatty acid-benzenediol derivatives and methods of making and using thereof
CN101193650A (zh) * 2005-04-08 2008-06-04 新河药品股份有限公司 抗滥用的苯丙胺前体药物
CA2613875C (en) 2005-07-04 2018-09-25 Ramu Krishnan Improved drug or pharmaceutical compounds and a preparation thereof
WO2008079838A1 (en) 2006-12-20 2008-07-03 Astrazeneca Ab Compounds and uses thereof
CA2641718A1 (en) 2006-02-09 2007-08-16 University Of Virginia Patent Foundation Bicyclic sphingosine 1-phosphate analogs
EP2077860B1 (en) * 2006-10-25 2014-04-09 Ramot at Tel-Aviv University Ltd Psychotropic agents having glutamate nmda activity
CN102781236B (zh) 2009-12-31 2015-01-07 凯姆制药公司 喹硫平的氨基酸缀合物、其制备和使用方法
DK2544536T3 (en) 2010-03-11 2019-02-04 Kempharm Inc FAT ACID CONJUGATES OF QUETIAPIN, METHOD OF PREPARING IT AND USING IT

Also Published As

Publication number Publication date
US10010615B2 (en) 2018-07-03
ES2548031T3 (es) 2015-10-13
US20140287050A1 (en) 2014-09-25
HK1210046A1 (zh) 2016-04-15
US20120276168A1 (en) 2012-11-01
CA2889457A1 (en) 2011-07-07
CA2964809C (en) 2019-07-02
CN102781236B (zh) 2015-01-07
CA2964809A1 (en) 2011-07-07
EP2519101A4 (en) 2013-06-26
EP2987789A1 (en) 2016-02-24
AU2010336981A1 (en) 2012-07-19
CN107714703A (zh) 2018-02-23
CA2785846C (en) 2015-07-07
AU2010336981B2 (en) 2014-04-10
EP2519101A1 (en) 2012-11-07
US20170246308A1 (en) 2017-08-31
JP5544024B2 (ja) 2014-07-09
JP2013516414A (ja) 2013-05-13
CN104586859B (zh) 2017-12-05
US20110183963A1 (en) 2011-07-28
CA2889457C (en) 2016-06-28
IL220664A (en) 2016-02-29
JP5753610B2 (ja) 2015-07-22
US9597403B2 (en) 2017-03-21
CA2927380A1 (en) 2011-07-07
CA2927380C (en) 2017-07-04
CN104586859A (zh) 2015-05-06
CA2785846A1 (en) 2011-07-07
US8715699B2 (en) 2014-05-06
US20170246307A1 (en) 2017-08-31
CN102781236A (zh) 2012-11-14
US20170209586A1 (en) 2017-07-27
WO2011082076A1 (en) 2011-07-07
JP2014159462A (ja) 2014-09-04
EP2519101B1 (en) 2015-08-19

Similar Documents

Publication Publication Date Title
HK1219731A1 (zh) 喹硫平的氨基酸綴合物、其製備和使用方法
HRP20190057T1 (hr) Konjugati kvetiapina s masnom kiselinom, postupak izrade i uporaba istih
IL237471A (en) Annals of [[(s1) –2– isopropoxy – 1 – methyl – 2 – oxo-ethyl] amino] –phenoxy – phosphoryl
HRP20130456T1 (en) Novel process for the preparation of amino acid derivatives
PL2462223T3 (pl) Oksydaza fruktozyloaminokwasowa
EP2291419A4 (en) POLYMACROMONOMER AND PROCESS FOR PRODUCING THE SAME
IL216305A0 (en) Solid forms and process for preparing
EG26786A (en) Fertilizers contain sulfur and process to manufacture
PL2151428T3 (pl) Nowy sposób syntezy agomelatyny
PL2358662T3 (pl) Sposób amonolizy kwasu 11-bromoundekanowego
PL2137206T3 (pl) Sposób wytwarzania kwasu tauroursodeoksycholowego
EP2436678A4 (en) TRIALLYLISOCYANURATE AND MANUFACTURING METHOD THEREFOR
EP2415869A4 (en) MODIFIED OLIGO-NUCLEIC ACID MOLECULE, PROCESS FOR PREPARATION AND USES THEREOF
SI2151429T1 (sl) Postopek za pripravo agomelatina
EG26332A (en) Process for the preparation of benzonoprons
EP2345635A4 (en) AMINO ACID DERIVATIVE
GB0713189D0 (en) Amino acid derivatives
EP2345733A4 (en) PROCESS FOR PREPARING N-PROTECTED AMINO ACID
GB0715712D0 (en) Amino acid derivatives
EP2489655A4 (en) PROCESS FOR PREPARING DIETHYLENE-TRIAMIN-PENTA-ACETIC DERIVATIVES AND DIETHYLENE-TRIAMIN-PENTA-ACETIC ACID DERIVATIVES
IL211382A0 (en) Process for the preparation of ethanedinitrile
EP2256210A4 (en) WICKEROL AND MANUFACTURING METHOD THEREFOR
GB0906872D0 (en) Amino acid derivatives
PL389321A1 (pl) Chiralny N-Cbz blokowany aminokwas dimetylocyklopropanu i sposób jego wytwarzania
HUP0900305A2 (en) Peptide derivatives, process for their preparation and their therapeutical use